Viking Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

• Viking Therapeutics Inc VKTX.OQ reported a quarterly adjusted loss of 41 cents​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of -26 cents. The mean expectation of fifteen analysts for the quarter was for a loss of 32 cents per share. Wall Street expected results to range from -44 cents to -16 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Viking Therapeutics Inc's reported EPS for the quarter was a loss of 41 cents​.

• The company reported a quarterly loss of $45.63 million.

• Viking Therapeutics Inc shares had risen by 5.5% this quarter and lost 36.7% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 10.3% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Viking Therapeutics Inc is $102.00

This summary was machine generated from LSEG data April 23 at 08:37 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)